Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Antibody-drug conjugates hitting this target abound.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
